Clinical trials in North America.
Majority of patients with Hodgkin lymphoma are cured with current therapy. The short and long-term toxicity of therapy is a current issue, most especially the radiation-induced second tumors and cardiac abnormalities. Optimal therapy of advanced disease is being compared to ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine). More intensive chemotherapy may result in higher response but greater toxicity. Regimens requiring radiotherapy are also at risk of long-term toxicity. New targeted biologic therapy is under current investigation.